<SEC-DOCUMENT>0001019687-13-002451.txt : 20130625
<SEC-HEADER>0001019687-13-002451.hdr.sgml : 20130625
<ACCEPTANCE-DATETIME>20130625153248
ACCESSION NUMBER:		0001019687-13-002451
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130620
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130625
DATE AS OF CHANGE:		20130625

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		13931985

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>CURRENT REPORT ON FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Pursuant to Section&nbsp;13 or 15(d)&nbsp;of
the Securities Exchange Act of 1934</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
June 20, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AETHLON MEDICAL, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 4%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 32%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Nevada</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(State or other jurisdiction</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">of incorporation)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">000-21846</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Commission File Number)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">13-3632859</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(IRS Employer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Identification Number)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 55%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 42%; font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">8910 University Center Lane, Suite 660</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">San Diego, California</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices)</P></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">92122</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Zip Code)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (858) 459-7800</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Not applicable</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 97%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT>&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">FORWARD LOOKING STATEMENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 45.8pt">This Form 8-K and other reports filed by Registrant
from time to time with the Securities and Exchange Commission (collectively the &quot;Filings&quot;) contain or may contain forward
looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management
as well as estimates and assumptions made by Registrant's management. When used in the Filings the words &quot;anticipate, &quot;believe&quot;,
&quot;estimate&quot;, &quot;expect&quot;, &quot;future&quot;, &quot;intend&quot;, &quot;plan&quot; or the negative of these terms
and similar expressions as they relate to Registrant or Registrant's management identify forward looking statements. Such statements
reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other
factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired
by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 45.8pt">Although Registrant believes that the expectations
reflected in the forward looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance
or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not
intend to update any of the forward-looking statements to conform these statements to actual results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01 Other Events.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 20, 2013, the United
States Food and Drug Administration (FDA) approved an Investigational Device Exemption that allows the Registrant to initiate human
feasibility studies of the Aethlon Hemopurifier&reg; in the United States. .</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="width: 64px">&nbsp;</TD>
    <TD STYLE="width: 13px">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Exhibit No.:</B></FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt"><B>Description:</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-indent: 13.8pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Press release issued June 25, 2013</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 48%"><FONT STYLE="font-size: 10pt">&nbsp;AETHLON MEDICAL, INC.</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: white 3pt solid">&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-bottom: white 3pt solid">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By:&nbsp;<U>/s/ James A. Joyce</U></P></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">James A. Joyce</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dated: June 25, 2013</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><IMG SRC="image_001.jpg" ALT="aethlon_logo" STYLE="height: 72px; width: 193px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aethlon Medical Announces FDA Approval of
IDE to Treat Hepatitis C (HCV) Patients</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>SAN DIEGO &ndash; June 25, 2013 &ndash;
Aethlon Medical, Inc.</B> (OTCQB: AEMD), announced today that the United States Food and Drug Administration (FDA) has approved
an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier&reg;
in the United States. The Hemopurifier<SUP>&reg;</SUP> is a first-in-class medical device that targets the rapid elimination of
life-threatening infectious disease and cancer glycopathogens from circulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the feasibility study protocol, Aethlon
will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies
required for market clearance to treat HCV and potentially other disease conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Obtaining FDA&rsquo;s permission to
initiate human studies has been our most important objective for several years,&rdquo; stated Jim Joyce, Chairman and CEO of Aethlon
Medical. &ldquo;I salute the perseverance of our dedicated Aethlon team, their families, and loyal shareholders whose support allowed
us to endure the challenges of navigating through FDA. We plan to reward your faith with clinical execution and progression toward
a marketable therapy in the United States.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specific to the treatment of HCV, the Hemopurifier
is uniquely positioned as an adjuvant to be incorporated with either interferon-based standard of care (SOC) or emerging all-antiviral
drug regimens without adding drug toxicity.&nbsp; In addition to augmenting the early viral kinetic response to SOC, the Hemopurifier
is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes
resistance to drug regimens. Additionally, the Hemopurifier addresses the large population of HCV-infected ESRD patients for which
SOC and emerging all-antiviral strategies may be contraindicated or not yet cleared. According to the World Health Organization
(WHO), HCV is a blood-borne pathogen that affects upwards of 170 million persons, or 2-3% of the world's population. It is a leading
cause of cirrhosis and liver transplantation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA approved Hemopurifier therapy feasibility
study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any
pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of
three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of
six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy
phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through
quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier
during each treatment session.</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In studies previously conducted in India, Hemopurifier
therapy was demonstrated to be well tolerated in treatment na&iuml;ve HIV and HCV-infected ESRD patients when included during normally
scheduled four-hour dialysis sessions. In these studies, average per treatment viral load reductions were observed to exceed 50%
in both disease conditions. In follow-on studies of non-ESRD individuals infected with HCV, a three-treatment protocol of Hemopurifier
therapy in combination with interferon-based standard of care (SOC) resulted in undetectable HCV in as little as seven days in
hardest to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion
HCV copies during a single six-hour treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&ldquo;Aethlon Medical has been laying the
groundwork necessary to implement the now approved clinical trial protocol for several years&rdquo; said Rod Kenley, Aethlon&rsquo;s
President. &ldquo;We are finally able to move forward with our contract research and clinical partners in finalizing all of the
activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done,
today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The feasibility study protocol was originally
designed as a human safety challenge and model for addressing drug and vaccine resistant bioterror and emerging pandemic threats
such as the Middle East Respiratory Syndrome (MERS) now spreading overseas. <I>In vitro </I>studies conducted by leading government
and non-government researchers have demonstrated that the Hemopurifier is able to capture a broad-spectrum of some of world&rsquo;s
deadliest viral pathogens. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever
(LHF), H5N1 avian influenza (Bird Flu), H1N1 swine flu virus, the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV)
and Vaccinia and Monkeypox (MPV), which serve as models for human smallpox infection. Human efficacy studies are not permissible
against high-threat bioterror and pandemic threats.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Hemopurifier is also being tested for its
ability to capture glycopathogen targets that initiate or enhance the progression of sepsis through a contract with the Defense
Advanced Research Projects Agency (DARPA). Sepsis is a life-threatening illness triggered by an overwhelming infection of the bloodstream.
Globally, there are 18 million cases of diagnosed sepsis per year and the incidence is rising at 8 to 10% annually.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In cancer, the Hemopurifier has been discovered
to capture tumor-derived exosomes underlying several forms of cancer.&nbsp; Tumor-derived exosomes have recently emerged to be
a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through
apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive
properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. &nbsp;By addressing
this unmet medical need, the Hemopurifier is positioned as an adjunct to improve established cancer treatment regimens. I<I>n vitro</I>
studies to date have also documented that the Hemopurifier captures exosomes underlying lymphoma, melanoma, ovarian, and breast
cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In design, the Aethlon Hemopurifier consists
of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of advanced plasma membrane
technology. The design allows for extracorporeal therapeutic delivery to occur on standard CRRT and dialysis instruments already
located in hospitals and clinics worldwide. The mechanism of the Hemopurifier to rapidly eliminate a broad-spectrum disease targets
is based on GNA&rsquo;s ability to selectively bind unique high mannose signatures that are abundant on the surface of cancer-secreted
exosomes and glycoproteins that reside on the outer membrane of infectious viral pathogens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will continue to update shareholders,
constituents and potential study participants as feasibility study milestones are achieved, including naming a principal investigator,
initiation of patient enrollment and the beginning of treatments with the Aethlon Hemopurifier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Aethlon Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Aethlon Medical creates innovative medical
devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT&trade;
System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal
of disease promoting particles from the entire circulatory system. &nbsp;At present, The Aethlon ADAPT product pipeline includes
the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract
with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit <FONT STYLE="text-underline-style: none; color: windowtext">www.aethlonmedical.com</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Certain statements herein may be forward-looking
and involve risks and uncertainties.&nbsp; Such forward-looking statements involve assumptions, known and unknown risks, uncertainties
and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different
from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the FDA will not approve the initiation of the Company's future clinical programs
or provide market clearance of the Company's products, future human studies whether revenue or non-revenue generating from either
compassionate use or non-compassionate use of the Aethlon ADAPT&trade; system or the Aethlon Hemopurifier&reg; as an adjunct therapy
to improve patient responsiveness to established cancer or hepatitis C therapies or sepsis therapies or as a standalone cancer
or hepatitis C therapy or standalone sepsis therapy, the approval of the Company&rsquo;s technologies or products as a treatment
against pandemic threats, the Company's ability to raise capital when needed, the Company's ability to complete the development
of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide
its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability
exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual
results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing
economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes
no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events,
or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Contacts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">James A. Joyce<BR>
Chairman and CEO<BR>
858.459.7800 x301<BR>
<FONT STYLE="color: blue">jj@aethlonmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Jim Frakes<BR>
Chief Financial Officer<BR>
858.459.7800 x300<BR>
<FONT STYLE="color: blue">jfrakes@aethlonmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Marc Robins<BR>
877.276.2467<BR>
<FONT STYLE="color: blue">mr@aethlonmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MVP!#`0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P``1"`!(`,$#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHI*`%J.:>*WB:6:1(XU&69S@#\:H:
M]KMKX?T]KJZ))/RQQK]Z1O0?XUX_KOB._P#$%P7O),1`_)`I^1/P[GW-=F%P
M<\1KLNYSUL1&EINST;4/B/HMFS)`9;QAWB7Y?S./TK*;XK19^729"/><`_RK
MSFBO6CEM!+57^9PO%U7LSU*S^)^ES,%NK:YML_Q8#C].?TKJ]/U.SU2#SK&Y
MCGC[E#G'U':O`JL6-_<Z;=+<V4[PS+_$IZ^Q'<>QK*KE=-K]V[,TAC)+XM3W
M^EKEO"'C&+Q!$;>X"Q7\:Y9!TD']Y?ZBNIKQ:E.5.3C):GH0FIKFB%%%%04%
M%0W=Y;V%K)<WD\<$$8R\DC!54>Y-<VWQ-\())L.NVV?4!B/S`Q0!U5%5;#4K
M/5;1;K3[F*YMWZ21,&!JE>^*=&TZX,%WJ,$<J]4W9(^N.E5&,I.T5<3DH[LU
MZ*SUUS37TV34%OH#9Q#=),'&U![^E<3X<^*]CJ&M:S%J]]I]I9VTH2R<,1YR
MY;YLD\\!>F.M)IIV8)WV/1J*\M\7:G))\5O"'V.[D-I<HCXCD(212Q(.!P<B
MNNO/B)X5L+IK>XUNU$JG:P4EP#[D`BD,Z2BJVGZC9ZK:)=:?<Q7-N_W9(F#`
MUYW\-KNXN/'OC..:XFDCBN<1H[E@@\R3H#TH`]-HK-UCQ%I.@1J^K7\%H'^Z
M)&P6^@ZFJFD^-_#NN7(M]-U:VFG/W8\E6;Z!L$_A0!NT54U+5;+1[-KO4;F.
MVMU(4R2'`!/2L[4O&OA[1UB:_P!6MH?.02(N[<S*1D'`R<&@#<IKL$4LQ`4#
M))["LS1O$^C>(0_]DZC;W10994;YE'J5/-5/'-\UAX3O&0D/*!"I'^T<'],U
M=.#G)174F4N6+D>8>*==?7]9DGW'[/&2D"^B^OU/6JFDZ/>ZW>?9K"+S)`NY
MB3A5'J35'H*]C\#Z!_8FAHTR8NKG$DN>H_NK^`_4FOH<36CA**4-]D>51@Z\
M[R^9PW_"N-?_`.>=M_W^_P#K4?\`"N-?_P">=M_W^_\`K5Z[7'_$[Q;_`,(I
MX5E>!]M]=YAML=5./F?\!^I%>9_:=?R.WZG3/,+^PN=,O)+2\B,4\?WE/Z$'
MN*KT_0-7E\4>'I8+N5YM4TI?,1W.7FMB>03U)0G/T/M3*]?"XA5Z:EUZGGUJ
M7LY\I-:74UC=Q7-LY2:)@R,.QKW'0M6CUO1[>^B`'FK\R_W6'!'YUX17HOPK
MOF,=_8L>%*S(/3/!_D*YLSHJ5/VBW7Y&V#J<L^7N>AT445X!ZA2U:VL+O39H
MM66![+`:59R`F`01NSQC('6N/N_'/A"&-M/TNS75I2,"TL+/S%;MC.-N*S?C
M;'.VGZ,\JSMI"76;X19Z?+C/X;\>YKH]!\5>#(8[2PT.]L8_/98XH($(8D],
MC&<^YH`\Z\`:G<:/X9\8/%&;21+E$2$'(@9BRD#W'3\!79^&-1TS1](A3^R-
M3EN)%WS3"R+>8QY/S=QZ5S?@?2CK4?CRR0@227V8R>FX/(1^HKKO#WC*RL=.
MBT[79&L+VT41,LRD!@.`0?I7;2UHM15W?6WX'-4TJ7;MH4-.ACN?'+&UTJYB
MTJ^A*W4-Q:E8V;!/*GCL/S-8WPWT32[WQ?XQANM-LYXH+S;$DD"LL8WR<*".
M!P.GI7HVF>)M,UF\>VTZX^T-&F]V53M`SCJ:\O\`"GBG3/!WC_Q=#KTKV?VF
MZ+QLT;,#AW/8$\A@16%>3E)<RM9&E**2T=Q?BCIAO?B-X8TVT<VJRPK`K1?+
MY:%R#MQTP,UZ-;^!O#=MIPLDT6Q,.W:=\(9C[ECSGWS7!^+;R+4/BOX)N[=B
MT,\4<L9(QE68D''T->M5B:GE7PG@&D>,_%NC6[O]BMYAY:,<XPS#\\8'X"G_
M``R(7X@>.">@NL_^1)*=\//^2I^-?^NQ_P#1C4WX8X/Q!\;@][K_`-J24`0?
M#G3+?QQK.L>*==A6\D%SY-K%,-R1*!GA3QP"`/Q/4UN?$OP;I=UX4O=1MK2&
MUO[",W$4\""-OEY(..O`/T.*Y_PWJ:?"KQ#JFCZ\DL6E7<WGV=X(RR>F#CVP
M#Z$>AS5_QM\0M/US19M`\+-)JFHZ@ODX@C;:B'[Q)(]./;.30!G^*];D\0_`
M6VU"X;=.[QI*WJRN5)_'&?QKIO`G@C2X/#5E>ZE907VHWD"333W*"0C*C"C.
M<`+@<>E8/CG0_P#A&_@?!I;,&D@:+S&7H7+Y;'XDUZ+X;_Y%C2O^O.'_`-`%
M`'F.NZ5:>%OC1X=DT:%;1;[`FBB&U#DE3@=LCMZBNO\`B?G_`(1B+T^TIG\F
MKG/'O_)8?!_U7_T8:[7QOISZGX5NHH4+S)MD15ZD@]/RS6^&DHUHM]S.LFZ;
M2///`F@_VSKBRS)FUM,2/D<,W\*_U_"O816/X5T-=!T.&V('G-^\F8=W/7\N
MGX5LU>,K^VJ-K9;$8>E[.%NHA(`))P*^8?B3XK;Q7XKFFC8FRMLP6P]5!Y;\
M3S],>E>X_$'7O[+T;[)`^+F\!08ZJG\1_I^-?/7B*P^S70GC7$<W7'9N]2L-
M-T?;=/ZU*]M'VGLROH&LS:!K5MJ-N-SPOED/213PRGV()'XUZ!JEM!!<)-9,
M7L+N,7%JY[QMV/NIRI^E>75WO@F__M?1KC0)3FYMMUU89ZL.LL0^H&X>X/K6
MN!Q'L:EGLS/$TN>%UNB>NU^%N?\`A(+OKC[-S_WT*XH<BO1?A78D1W]\PX8K
M"A]<<G^8KV,?)1P\KG!AE>JCT.BBBOFCV!KHLBE74,I&"",@BJL.CZ=;2B6W
MT^TBD'1TA52/Q`JY10`Q(HXRQ1%4L<G:,9IDUI;W&//@BEQTWH&Q^=344;!8
MBBMXH%VPQ1QCT10/Y5%<:98W<@DNK*VF<#`:2)6(_$BK5)0!1DO=/AU.WL9&
MB6[="T,97G:/3CCI4+^)=*2.YD:\39;2B&8@$[7)P!TY_"LKQ'I&H7.JC4-/
MA#SVT"-;DL`&<.<K^*DUER>%M0M],O+>&!I'>:UE#(ZAG*\R,">ASGK75"E2
M:3E+M^>IA*I--I(Z8>(=&B@-V)E2-Y/*W^2P+/C.,8R>*=#KNCFVDNX;B$1B
M18Y&"D$,3@`C&>2>]9%W::C+:Z=)'97LCVE^)F2XG1I&3:>ASCJ>E5]0T75-
M3-_>FS$,EQ);*EOYBEML;Y+,1QGGIZ"A4J;W?XKN#J3Z(W[_`%C2!<-87KQR
MR9&^(Q&0+GINP"!^-.BFT?2]233X$M;:[G7<L4<84N.?0>QK.L8M0T74=05=
M.>[AO+HSI/%(H(W8R&#$'C';-9MQX<U:[2ZU8R-'J1N!/#:_(5PAPBENHRN>
MAQS4JG3;U>GZ@ZDTMCK(;JTU#SXXRDWD2&.52N=KCG'/UJ=Y$MX6=L+'&I)/
M8`5S>DF_TJ\U)I]+G,-S=-<>:KH0BE1U&<\8/2MAI)-2T)Y%@DB>X@;;%)@,
M,@X!]#6<X<KTV-(SNO,8FL:3=7EI&L\+W%S%YUN"O+)Z@D>QITVNZ=!;//+=
M(L:2F$DYSO'!4#J3]*YJ'PK=W"6:S)]GFMM,B2*8,"8KA7R/_K^QHM-(UB*.
MRU&>QC>ZM[R>>6U$@^82<;E/3([9K9TJ727]?U]QE[2IV.ML;Z#4;?SK9BR9
M*Y9"IR/8@&I9ID@B>65@L:*69CT`'4U3M[Z[F\@OILT(D9@^^1,Q@#@G!.<]
M.*YCXF:K-:Z3'90HX2Z/[V4`[0H_ASZD_H*SI4G4J*"ZFDZG)!R9P/B'67U[
M6I[ULB,G;$I_A0=/\?QK$O[-;ZSD@;JPRI]#VJQ17TZIQ4/9VTV/&YWS<W4\
M^DC:*1D<893@CT-3:=?W&EZC;WMFYCN+>021MZ$'-=;<Z-9W<[32QMO;J5;&
M:=8^#H=2NEMK*UGFF;^%7/'N3V%>)/+:D;NZL>E'&0=E9W.@GM1K%Q8WFCQ9
MAU8;XHU_Y9R9Q)&?]TY_`BO9-#TF/1-(M[&(@B)?F;^\QY)_.L3P+X+B\(Z4
MT)D:6:5_-8$[EB8C!V_48R>^*ZNN>OB95(QIOI^)I2HQA)R74****Y3<****
M`"BBB@`HHHH`2C%%%`!BC%%%`!BBBB@`Q1110`48HHH`,4R:"*XB:*:-)(V&
M&5QD'\***`.6U#X<:+>,7MUEM&/:)LK^1S^E93?"B/=\NK.![P`G^=%%=$<;
M7BK*1B\/2>Z+EG\,-+A<-=7%S<X_AR$'Z<_K75Z?IEGI<'DV-M'`G<(,9^IZ
;FBBHJ5ZE7XY7*A2A#X46J6BBLC0****`/__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
